肿瘤相关巨噬细胞的研究进展

doi:10.11958/20241415

天津医药 ›› 2025, Vol. 53 ›› Issue (1): 108-112.doi: 10.11958/20241415

• 综述 • 上一篇

肿瘤相关巨噬细胞的研究进展

郝成飞¹^,²^,³^,⁴^,⁵(), 陈国杉²^,³, 张西波¹^,⁴^,⁵, 戚峰²^,³^,^△()

1 天津医科大学附属南开医院肝胆胰外科（邮编300110）
2 天津医科大学总医院普外科
3 天津市精准血管重建和器官功能修复重点实验室
4 天津市急腹症器官损伤与中西医修复重点实验室
5 天津市中西医结合急腹症研究所

收稿日期:2024-09-24 修回日期:2024-11-11 出版日期:2025-01-15 发布日期:2025-02-06
通讯作者: ^△E-mail：fengqi01@tmu.edu.cn
作者简介:郝成飞（1986），男，主治医师，主要从事肝胆胰胃肠系统良恶性疾病以及器官移植方面研究。E-mail：nkyyhcf@163.com
基金资助:
国家自然科学基金资助项目(82170399);天津市教育委员会科学研究项目(2024KJ242)

A review of the research progress on tumor-associated macrophages

HAO Chengfei¹^,²^,³^,⁴^,⁵(), CHEN Guoshan²^,³, ZHANG Xibo¹^,⁴^,⁵, QI Feng²^,³^,^△()

1 Department of Hepatobiliary and Pancreatic Surgery, Tianjin Nankai Hospital, Tianjin Medical University, Tianjin 300110, China
2 Department of General Surgery, Tianjin Medical University General Hospital
3 Tianjin Key Laboratory of Precise Vascular Reconstruction and Organ Function Repair
4 Tianjin Key Laboratory of Acute Abdomen Disease Associated Organ Injury and ITCWM Repair
5 Institute of Integrative Medicine for Acute Abdominal Diseases

Received:2024-09-24 Revised:2024-11-11 Published:2025-01-15 Online:2025-02-06
Contact: ^△E-mail：fengqi01@tmu.edu.cn

郝成飞, 陈国杉, 张西波, 戚峰. 肿瘤相关巨噬细胞的研究进展[J]. 天津医药, 2025, 53(1): 108-112.

HAO Chengfei, CHEN Guoshan, ZHANG Xibo, QI Feng. A review of the research progress on tumor-associated macrophages[J]. Tianjin Medical Journal, 2025, 53(1): 108-112.

摘要/Abstract

摘要：

在肿瘤微环境中，肿瘤相关巨噬细胞通过高度可塑性构建复杂交互网络，促进癌症生态系统动态演变。随着单细胞测序技术的革新，肿瘤相关巨噬细胞的异质性、功能多样性及其与肿瘤微环境的相互作用机制得以揭示。这预示着肿瘤相关巨噬细胞或成为肿瘤靶向治疗新靶标，推动精准抗癌策略发展。该文综述相关研究历程，探讨交互机制，阐述分类及临床治疗潜力，旨在为肿瘤学研究与临床实践提供新视角和指导。

Abstract:

In the tumor microenvironment, tumor-associated macrophages construct complex interaction networks through highly plasticity, promoting the dynamic evolution of the cancer ecosystem. With the innovation of single-cell sequencing technology, the heterogeneity, functional diversity, and interaction mechanisms of tumor-associated macrophages with tumor microenvironment have been revealed. This suggests that tumor-associated macrophages may become a new target for tumor targeted therapy, driving the development of precision anti-cancer strategies. This review summarizes the relevant research progress, explores the interaction mechanisms, describes the classification and clinical therapeutic potential, aiming to provide new perspectives and guidance for tumor research and clinical practice.

Key words: tumor-associated macrophages, tumor microenvironment, myeloid cells, RNA-Seq, cell communication

中图分类号:

R730.3

参考文献 40

[1]	KLOOSTERMAN D J, AKKARI L. Macrophages at the interface of the co-evolving cancer ecosystem[J]. Cell, 2023, 186(8):1627-1651. doi:10.1016/j.cell.2023.02.020.
[2]	CHRISTOFIDES A, STRAUSS L, YEO A, et al. The complex role of tumor-infiltrating macrophages[J]. Nat Immunol, 2022, 23(8):1148-1156. doi:10.1038/s41590-022-01267-2.
[3]	CASSETTA L, POLLARD J W. A timeline of tumour-associated macrophage biology[J]. Nat Rev Cancer, 2023, 23(4):238-257. doi:10.1038/s41568-022-00547-1.
[4]	EVANS R, ALEXANDER P. Cooperation of immune lymphoid cells with macrophages in tumour immunity[J]. Nature, 1970, 228(5272):620-622. doi:10.1038/228620a0.
[5]	BISWAS S K, ALLAVENA P, MANTOVANI A. Tumor-associated macrophages:functional diversity, clinical significance,and open questions[J]. Semin Immunopathol, 2013, 35(5):585-600. doi:10.1007/s00281-013-0367-7.
[6]	MANTOVANI A, SICA A, SOZZANI S, et al. The chemokine system in diverse forms of macrophage activation and polarization[J]. Trends Immunol, 2004, 25(12):677-686. doi:10.1016/j.it.2004.09.015.
[7]	MURRAY P J, ALLEN J E, BISWAS S K, et al. Macrophage activation and polarization:nomenclature and experimental guidelines[J]. Immunity, 2014, 41(1):14-20. doi:10.1016/j.immuni.2014.06.008.
[8]	YANG M, MCKAY D, POLLARD J W, et al. Diverse functions of macrophages in different tumor microenvironments[J]. Cancer Res, 2018, 78(19):5492-5503. doi:10.1158/0008-5472.CAN-18-1367.
[9]	QIAN Y, YIN Y, ZHENG X, et al. Metabolic regulation of tumor-associated macrophage heterogeneity:insights into the tumor microenvironment and immunotherapeutic opportunities[J]. Biomark Res, 2024, 12(1):1. doi:10.1186/s40364-023-00549-7.
[10]	CHE L H, LIU J W, HUO J P, et al. A single-cell atlas of liver metastases of colorectal cancer reveals reprogramming of the tumor microenvironment in response to preoperative chemotherapy[J]. Cell Discov, 2021, 7(1):80. doi:10.1038/s41421-021-00312-y.
[11]	CHENG S, LI Z, GAO R, et al. A pan-cancer single-cell transcriptional atlas of tumor infiltrating myeloid cells[J]. Cell, 2021, 184(3):792-809.e23. doi:10.1016/j.cell.2021.01.010.
[12]	MA R Y, BLACK A, QIAN B Z. Macrophage diversity in cancer revisited in the era of single-cell omics[J]. Trends Immunol, 2022, 43(7):546-563. doi:10.1016/j.it.2022.04.008.
[13]	BILL R, WIRAPATI P, MESSEMAKER M, et al. CXCL9:SPP1 macrophage polarity identifies a network of cellular programs that control human cancers[J]. Science, 2023, 381(6657):515-524. doi:10.1126/science.ade2292.
[14]	TAURIELLO D, BATLLE E. Targeting the microenvironment in advanced colorectal cancer[J]. Trends Cancer, 2016, 2(9):495-504. doi:10.1016/j.trecan.2016.08.001.
[15]	MOCHIZUKI S, AO T, SUGIURA T, et al. Expression and function of a disintegrin and metalloproteinases in cancer-associated fibroblasts of colorectal cancer[J]. Digestion, 2020, 101(1):18-24. doi:10.1159/000504087.
[16]	KRISHNAN V, CHONG Y L, TAN T Z, et al. TGFβ promotes genomic instability after loss of RUNX3[J]. Cancer Res, 2018, 78(1):88-102. doi:10.1158/0008-5472.CAN-17-1178.
[17]	ZHANG R, QI F, ZHAO F, et al. Cancer-associated fibroblasts enhance tumor-associated macrophages enrichment and suppress NK cells function in colorectal cancer[J]. Cell Death Dis, 2019, 10(4):273. doi:10.1038/s41419-019-1435-2.
[18]	ZHOU W, GUO S, LIU M, et al. Targeting CXCL12/CXCR4 axis in tumor immunotherapy[J]. Curr Med Chem, 2019, 26(17):3026-3041. doi:10.2174/0929867324666170830111531.
[19]	CHO H, SEO Y, LOKE K M, et al. Cancer-stimulated CAFs enhance monocyte differentiation and protumoral TAM activation via IL6 and GM-CSF secretion[J]. Clin Cancer Res, 2018, 24(21):5407-5421. doi:10.1158/1078-0432.CCR-18-0125.
[20]	CASANOVA-ACEBES M, DALLA E, LEADER A M, et al. Tissue-resident macrophages provide a pro-tumorigenic niche to early NSCLC cells[J]. Nature, 2021, 595(7868):578-584. doi:10.1038/s41586-021-03651-8.
[21]	ENGBLOM C, PFIRSCHKE C, PITTET M J. The role of myeloid cells in cancer therapies[J]. Nat Rev Cancer, 2016, 16(7):447-462. doi:10.1038/nrc.2016.54.
[22]	秦雅含, 张珂, 张梦雨, 等. MDSC靶向免疫治疗胰腺癌的研究进展[J]. 上海交通大学学报(医学版), 2023, 43(10):1317-1323.
	QIN Y H, ZAHGN K, ZHANG M Y, et al. Research progress of MDSCs-targeted immunotherapy for pancreatic cancer[J]. Journal of Shanghai Jiaotong University(Medical Science), 2023, 43(10):1317-1323. doi:10.3969/j.issn.1674-8115.2023.10.014.
[23]	GERHARD G M, BILL R, MESSEMAKER M, et al. Tumor-infiltrating dendritic cell states are conserved across solid human cancers[J]. J Exp Med, 2021, 218(1):e20200264. doi:10.1084/jem.20200264.
[24]	WU J, LU A D, ZHANG L P, et al. Study of clinical outcome and prognosis in pediatric core binding factor-acute myeloid leukemia[J]. Zhonghua Xue Ye Xue Za Zhi, 2019, 40(1):52-57. doi:10.3760/cma.j.issn.0253-2727.2019.01.010.
[25]	SIWICKI M, PITTET M J. Versatile neutrophil functions in cancer[J]. Semin Immunol, 2021,57:101538. doi:10.1016/j.smim.2021.101538.
[26]	MANTOVANI A, ALLAVENA P, MARCHESI F, et al. Macrophages as tools and targets in cancer therapy[J]. Nat Rev Drug Discov, 2022, 21(11):799-820. doi:10.1038/s41573-022-00520-5.
[27]	BEJARANO L, JORDĀO M, JOYCE J A. Therapeutic targeting of the tumor microenvironment[J]. Cancer Discov, 2021, 11(4):933-959. doi:10.1158/2159-8290.CD-20-1808.
[28]	PITTET M J, MICHIELIN O, MIGLIORINI D. Clinical relevance of tumour-associated macrophages[J]. Nat Rev Clin Oncol, 2022, 19(6):402-421. doi:10.1038/s41571-022-00620-6.
[29]	JING L, AN Y, CAI T, et al. A subpopulation of CD146⁺ macrophages enhances antitumor immunity by activating the NLRP3 inflammasome[J]. Cell Mol Immunol, 2023, 20(8):908-923. doi:10.1038/s41423-023-01047-4.
[30]	WANG X, XU Y, SUN Q, et al. New insights from the single-cell level:tumor associated macrophages heterogeneity and personalized therapy[J]. Biomed Pharmacother, 2022,153:113343. doi:10.1016/j.biopha.2022.113343.
[31]	XIANG X, WANG J, LU D, et al. Targeting tumor-associated macrophages to synergize tumor immunotherapy[J]. Signal Transduct Target Ther, 2021, 6(1):75. doi:10.1038/s41392-021-00484-9.
[32]	CASSIER P A, ITALIANO A, GOMEZ-ROCA C A, et al. CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue:a dose-escalation and dose-expansion phase 1 study[J]. Lancet Oncol, 2015, 16(8):949-956. doi:10.1016/S1470-2045(15)00132-1.
[33]	NYWENING T M, WANG-GILLAM A, SANFORD D E, et al. Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer:a single-centre, open-label,dose-finding,non-randomised,phase 1b trial[J]. Lancet Oncol, 2016, 17(5):651-662. doi:10.1016/S1470-2045(16)00078-4.
[34]	JIAO X, VELASCO-VELÁZQUEZ M A, WANG M, et al. CCR5 governs DNA damage repair and breast cancer stem cell expansion[J]. Cancer Res, 2018, 78(7):1657-1671. doi:10.1158/0008-5472.CAN-17-0915.
[35]	HALAMA N, ZOERNIG I, BERTHEL A, et al. Tumoral immune cell exploitation in colorectal cancer metastases can be targeted effectively by anti-CCR5 therapy in cancer patients[J]. Cancer Cell, 2016, 29(4):587-601. doi:10.1016/j.ccell.2016.03.005.
[36]	LIU J, WANG C, MA X, et al. High expression of CCR5 in melanoma enhances epithelial-mesenchymal transition and metastasis via TGFβ1[J]. J Pathol, 2019, 247(4):481-493. doi:10.1002/path.5207.
[37]	HUGHES R, QIAN B Z, ROWAN C, et al. Perivascular M2 macrophages stimulate tumor relapse after chemotherapy[J]. Cancer Res, 2015, 75(17):3479-3491. doi:10.1158/0008-5472.CAN-14-3587.
[38]	GUO F, WANG Y, LIU J, et al. CXCL12/CXCR4:a symbiotic bridge linking cancer cells and their stromal neighbors in oncogenic communication networks[J]. Oncogene, 2016, 35(7):816-826. doi:10.1038/onc.2015.139.
[39]	WEISKOPF K, RING A M, HO C C, et al. Engineered SIRPα variants as immunotherapeutic adjuvants to anticancer antibodies[J]. Science, 2013, 341(6141):88-91. doi:10.1126/science.1238856.
[40]	DECZKOWSKA A, WEINER A, AMIT I. The physiology,pathology,and potential therapeutic applications of the TREM2 signaling pathway[J]. Cell, 2020, 181(6):1207-1217. doi:10.1016/j.cell.2020.05.003.

肿瘤相关巨噬细胞的研究进展

A review of the research progress on tumor-associated macrophages

引用本文

RichHTML

PDF (PC)

可视化

摘要/Abstract

使用本文

参考文献 40

相关文章 12

编辑推荐

Metrics

本文评价

[1]	刘丹阳, 李永涛, 张海燕, 李林, 刘洋, 沈雷. 乳腺癌细胞条件培养基对骨髓间充质干细胞生物学行为的影响[J]. 天津医药, 2024, 52(5): 454-458.
[2]	张彩蝶, 靳艳, 张德德. 润肺益肾饮对肺癌荷瘤大鼠的抑瘤作用和肿瘤免疫微环境的影响[J]. 天津医药, 2024, 52(4): 362-366.
[3]	司吴雪蓉, 蒋明. 类器官在癌症基础研究和临床转化中的应用[J]. 天津医药, 2024, 52(1): 28-32.
[4]	汤晓霞, 邓皖利, 张勇, 陈彬, 柴妮, 张澍, 谢曼丽. 逍遥散通过调节肿瘤免疫微环境抑制肺转移前微环境形成[J]. 天津医药, 2023, 51(3): 263-268.
[5]	刘丹阳, 王璐璐, 何军, 姜杨, 李永涛, 张晓东, 李鹏辉, 沈雷. 乳腺癌细胞培养上清液促进人脂肪间充质干细胞迁移和增殖的机制探讨[J]. 天津医药, 2023, 51(11): 1153-1157.
[6]	刘淑娟, 刘梦莹, 苏乌云, 窦佳, 王薇. 肿瘤相关巨噬细胞通过激活IGF-1R信号通路诱导三阴性乳腺癌细胞对白蛋白紫杉醇耐药的研究[J]. 天津医药, 2023, 51(11): 1158-1163.
[7]	于淼, 陈卫, 孙杨, 李彬, 牛昱光. 血清sTREM1联合ABCD-3I评分对短暂性脑缺血发作患者近期缺血性脑卒中的预测价值分析[J]. 天津医药, 2022, 50(11): 1201-1204.
[8]	余贤哲, 朱玲玲, 李建国. 肝细胞癌的血管正常化与免疫治疗 #br#[J]. 天津医药, 2021, 49(2): 219-224.
[9]	胡玲娟 , 何翔 , 张雷 , 冉琴 , 李国平 . 基于转录组测序探究PM2.5损伤肺上皮细胞 BEAS-2B的相关机制[J]. 天津医药, 2020, 48(1): 1-7.
[10]	李朋, 钱彪, 申茂磊, 赵国立, 王勤章. 缝隙连接蛋白-43在糖尿病膀胱豚鼠模型中的表达及意义[J]. 天津医药, 2020, 48(1): 25-29.
[11]	张新羽, 闫会敏. 髓系抑制性细胞在肝癌发病中的作用研究进展[J]. 天津医药, 2018, 46(12): 1352-1356.
[12]	汪玲，赵鹏飞，吕一品，郭静艺，孙鸣，吴慧哲，魏敏杰. 肿瘤微环境对乳腺癌发生发展的影响[J]. 天津医药, 2016, 44(4): 413-417.